DPP7

Summary

DPP7 (dipeptidyl peptidase 7, HGNC:14892) is a protein-coding gene on chromosome 9q34.3, encoding Dipeptidyl peptidase 2 (Q9UHL4). Plays an important role in the degradation of some oligopeptides.

The protein encoded by this gene is a post-proline cleaving aminopeptidase expressed in quiescent lymphocytes. The resting lymphocytes are maintained through suppression of apoptosis, a state which is disrupted by inhibition of this novel serine protease. The enzyme has strong sequence homology with prolylcarboxypeptidase and is active at both acidic and neutral pH.

Source: NCBI Gene 29952 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 176 total
• GTEx eGene: eQTL in 45 tissues, sQTL in 50 (q < 0.05)
• ChEMBL bioactivity: 3 clinical-phase molecules tested; no curated mechanism-of-action drug
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 1.71 (unconstrained)
• MANE Select transcript: NM_013379
• Notable: 176 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14892
Approved symbol	DPP7
Name	dipeptidyl peptidase 7
Location	9q34.3
Locus type	gene with protein product
Status	Approved
Aliases	DPPII, DPP2
Ensembl gene	ENSG00000176978
Ensembl biotype	protein_coding
OMIM	610537
Entrez	29952

Gene structure

Transcript identifiers

Ensembl transcripts: 65 — 28 nonsense_mediated_decay, 19 protein_coding, 13 retained_intron, 5 protein_coding_CDS_not_defined

MANE Select: ENST00000371579

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 1, TSL 2: 4, TSL 3: 4, TSL 5: 4

ENST00000371579, ENST00000460830, ENST00000463619, ENST00000470766, ENST00000472306, ENST00000473532, ENST00000473703, ENST00000478597, ENST00000482088, ENST00000483783, ENST00000485456, ENST00000491807, ENST00000497375, ENST00000706871, ENST00000706872, ENST00000706873, ENST00000706874, ENST00000706875, ENST00000706876, ENST00000706877, ENST00000706878, ENST00000706879, ENST00000706880, ENST00000706881, ENST00000706882, ENST00000718334, ENST00000718335, ENST00000894943, ENST00000894944, ENST00000894945, ENST00000894946, ENST00000894947, ENST00000894948, ENST00000894949, ENST00000894950, ENST00000960839, ENST00000960840, ENST00000960841, ENST00000974671, ENST00000974674, ENST00000974676, ENST00001043763, ENST00001043764, ENST00001043765, ENST00001043766, ENST00001043767, ENST00001043768, ENST00001043770, ENST00001043771, ENST00001043772, ENST00001043775, ENST00001043777, ENST00001043778, ENST00001043779, ENST00001043780, ENST00001043781, ENST00001043782, ENST00001043783, ENST00001043784, ENST00001043785, ENST00001043786, ENST00001074124, ENST00001119542, ENST00001128159, ENST00001133320

RefSeq mRNA: 4 — MANE Select: NM_013379 NM_001438108, NM_001438109, NM_001438110, NM_013379

CCDS: CCDS7030

Canonical transcript exons

ENST00000371579 — 13 exons

Exon	Start	End
ENSE00001455574	137114647	137114733
ENSE00001923377	137114463	137114576
ENSE00003495678	137114243	137114382
ENSE00003538243	137113361	137113496
ENSE00003567909	137113206	137113287
ENSE00003570670	137112953	137113119
ENSE00003576072	137112112	137112230
ENSE00003609068	137113865	137114028
ENSE00003670167	137112745	137112805
ENSE00004034807	137111690	137111754
ENSE00004034808	137111873	137112029
ENSE00004034809	137110546	137110783
ENSE00004034810	137110880	137110950

Expression profiles

Bgee: expression breadth ubiquitous, 243 present calls, max score 99.31.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 61.1705 / max 398.7661, expressed in 1755 samples.

Highest expression (Bgee): adenohypophysis, hemisphere of cerebellum, uterine tube, granulocyte, lobe of thyroid gland.

Genetic regulation across tissues (GTEx eQTL / sQTL)

DPP7 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 45 tissues and its splicing (sQTL) in 50 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 95 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Thyroid	sqtl	2.0e-122	-1.05	9:137111973:C:G
Adipose Subcutaneous	sqtl	4.4e-121	-0.91	9:137111973:C:G
Skin Not Sun Exposed Suprapubic	sqtl	3.4e-112	-1.00	9:137111973:C:G
Cells Cultured fibroblasts	sqtl	2.1e-103	-1.20	9:137111973:C:G
Skin Sun Exposed Lower leg	sqtl	9.4e-79	-0.92	9:137111973:C:G
Muscle Skeletal	sqtl	3.4e-77	-0.73	9:137111973:C:G
Testis	sqtl	9.8e-77	-1.24	9:137111973:C:G
Artery Tibial	sqtl	2.3e-72	-0.80	9:137111973:C:G
Heart Atrial Appendage	sqtl	1.3e-69	-1.07	9:137111973:C:G
Nerve Tibial	sqtl	6.8e-67	-0.76	9:137111973:C:G
Whole Blood	sqtl	1.9e-66	-0.83	9:137111973:C:G
Adipose Visceral Omentum	sqtl	2.0e-66	-0.93	9:137111973:C:G
Esophagus Muscularis	sqtl	1.5e-65	-0.83	9:137111973:C:G
Cells EBV-transformed lymphocytes	sqtl	2.7e-59	-1.33	9:137111973:C:G
Artery Aorta	sqtl	6.2e-59	-0.92	9:137111973:C:G
Breast Mammary Tissue	sqtl	8.6e-53	-0.95	9:137111973:C:G
Adrenal Gland	sqtl	1.0e-52	-1.21	9:137111973:C:G
Colon Transverse	sqtl	2.2e-47	-0.85	9:137111973:C:G
Heart Left Ventricle	sqtl	9.6e-46	-0.94	9:137111973:C:G
Cells Cultured fibroblasts	eqtl	5.0e-44	-0.40	9:137114298:G:C

FANTOM5 promoters

1 alternative TSS:

Promoter ID	TPM avg	Samples expressed
103305	61.1705	1755

Top tissues by expression

showing 100 of 251 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adenohypophysis	UBERON:0002196	99.31	gold quality
right hemisphere of cerebellum	UBERON:0014890	99.14	gold quality
right uterine tube	UBERON:0001302	99.07	gold quality
granulocyte	CL:0000094	99.00	gold quality
right lobe of thyroid gland	UBERON:0001119	98.95	gold quality
cerebellar hemisphere	UBERON:0002245	98.93	gold quality
left testis	UBERON:0004533	98.93	gold quality
left lobe of thyroid gland	UBERON:0001120	98.91	gold quality
apex of heart	UBERON:0002098	98.91	gold quality
right testis	UBERON:0004534	98.91	gold quality
right frontal lobe	UBERON:0002810	98.88	gold quality
cerebellar cortex	UBERON:0002129	98.84	gold quality
left adrenal gland cortex	UBERON:0035825	98.72	gold quality
Brodmann (1909) area 9	UBERON:0013540	98.69	gold quality
right adrenal gland cortex	UBERON:0035827	98.64	gold quality
pituitary gland	UBERON:0000007	98.62	gold quality
left adrenal gland	UBERON:0001234	98.61	gold quality
right atrium auricular region	UBERON:0006631	98.59	gold quality
lower esophagus mucosa	UBERON:0035834	98.58	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	98.54	gold quality
right adrenal gland	UBERON:0001233	98.50	gold quality
minor salivary gland	UBERON:0001830	98.49	gold quality
anterior cingulate cortex	UBERON:0009835	98.44	gold quality
body of stomach	UBERON:0001161	98.32	gold quality
metanephros cortex	UBERON:0010533	98.32	gold quality
muscle layer of sigmoid colon	UBERON:0035805	98.31	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	98.23	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	98.20	gold quality
right coronary artery	UBERON:0001625	98.19	gold quality
lower esophagus	UBERON:0013473	98.19	gold quality
lower esophagus muscularis layer	UBERON:0035833	98.19	gold quality
skin of abdomen	UBERON:0001416	98.17	gold quality
spleen	UBERON:0002106	98.15	gold quality
mucosa of stomach	UBERON:0001199	98.13	gold quality
thyroid gland	UBERON:0002046	98.13	gold quality
body of pancreas	UBERON:0001150	98.11	gold quality
skin of leg	UBERON:0001511	98.09	gold quality
cardiac atrium	UBERON:0002081	98.02	gold quality
adrenal cortex	UBERON:0001235	98.00	gold quality
small intestine Peyer’s patch	UBERON:0003454	98.00	gold quality
upper lobe of left lung	UBERON:0008952	97.96	gold quality
ascending aorta	UBERON:0001496	97.94	gold quality
left coronary artery	UBERON:0001626	97.92	gold quality
thoracic aorta	UBERON:0001515	97.89	gold quality
tibial nerve	UBERON:0001323	97.88	gold quality
hypothalamus	UBERON:0001898	97.83	gold quality
right lung	UBERON:0002167	97.83	gold quality
nucleus accumbens	UBERON:0001882	97.76	gold quality
omental fat pad	UBERON:0010414	97.76	gold quality
left uterine tube	UBERON:0001303	97.75	gold quality
peritoneum	UBERON:0002358	97.70	gold quality
right ovary	UBERON:0002118	97.67	gold quality
putamen	UBERON:0001874	97.63	gold quality
saliva-secreting gland	UBERON:0001044	97.55	gold quality
caudate nucleus	UBERON:0001873	97.54	gold quality
descending thoracic aorta	UBERON:0002345	97.52	gold quality
cerebellum	UBERON:0002037	97.51	gold quality
right lobe of liver	UBERON:0001114	97.49	gold quality
coronary artery	UBERON:0001621	97.46	gold quality
endocervix	UBERON:0000458	97.43	gold quality
left ovary	UBERON:0002119	97.33	gold quality
vermiform appendix	UBERON:0001154	97.29	gold quality
stromal cell of endometrium	CL:0002255	97.25	gold quality
adipose tissue of abdominal region	UBERON:0007808	97.16	gold quality
amygdala	UBERON:0001876	97.13	gold quality
prefrontal cortex	UBERON:0000451	97.05	gold quality
adrenal gland	UBERON:0002369	97.05	gold quality
heart left ventricle	UBERON:0002084	97.03	gold quality
spinal cord	UBERON:0002240	97.00	gold quality
esophagus	UBERON:0001043	96.96	gold quality
body of uterus	UBERON:0009853	96.91	gold quality
transverse colon	UBERON:0001157	96.86	gold quality
upper lobe of lung	UBERON:0008948	96.84	gold quality
testis	UBERON:0000473	96.82	gold quality
mouth mucosa	UBERON:0003729	96.73	gold quality
lymph node	UBERON:0000029	96.70	gold quality
cardiac ventricle	UBERON:0002082	96.56	gold quality
esophagus mucosa	UBERON:0002469	96.31	gold quality
ectocervix	UBERON:0012249	96.28	gold quality
leukocyte	CL:0000738	96.10	gold quality
monocyte	CL:0000576	96.09	gold quality
heart	UBERON:0000948	96.06	gold quality
aorta	UBERON:0000947	95.99	gold quality
small intestine	UBERON:0002108	95.98	gold quality
zone of skin	UBERON:0000014	95.93	gold quality
gall bladder	UBERON:0002110	95.81	gold quality
hindlimb stylopod muscle	UBERON:0004252	95.79	gold quality
stomach	UBERON:0000945	95.76	gold quality
mucosa of transverse colon	UBERON:0004991	95.75	gold quality
gastrocnemius	UBERON:0001388	95.71	gold quality
cortex of kidney	UBERON:0001225	95.44	gold quality
subcutaneous adipose tissue	UBERON:0002190	95.34	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	95.31	gold quality
neocortex	UBERON:0001950	95.22	gold quality
muscle of leg	UBERON:0001383	95.14	gold quality
bone marrow cell	CL:0002092	95.09	gold quality
tendon of biceps brachii	UBERON:0008188	95.04	gold quality
fundus of stomach	UBERON:0001160	94.87	gold quality
frontal cortex	UBERON:0001870	94.84	gold quality
prostate gland	UBERON:0002367	94.83	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-HCAD-13	yes	11.77
E-GEOD-93593	yes	4.01
E-MTAB-9221	no	685.06
E-ANND-3	no	0.00

HPA expression

RNA tissue specificity: Low tissue specificity

showing 60 of 80 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Choroid plexus	tissue	132.4
Pituitary gland	tissue	101.2
Salivary gland	tissue	73.1	medium
Pancreas	tissue	54.9	medium
Locus coeruleus	tissue	49.3
Parathyroid gland	tissue	46.9	medium
Nucleus accumbens	tissue	44.7
Vagina	tissue	43.0	low
Heart muscle	tissue	39.8	low
Hippocampus	tissue	39.3	low
Seminal vesicle	tissue	38.4	medium
Postcentral gyrus	tissue	37.3
Adrenal gland	tissue	34.0	high
Bone marrow	tissue	31.3	high
Adipose tissue	tissue	30.0	medium
Thyroid gland	tissue	27.4	medium
Spinal cord	tissue	25.6
Spleen	tissue	24.7	medium
Fallopian tube	tissue	24.5	medium
Prostate	tissue	24.4	medium
Skeletal muscle	tissue	24.2	not detected
Superior colliculi	tissue	24.1
Stomach 1	tissue	23.9	medium
Medulla oblongata	tissue	23.0
Lung	tissue	22.9	high
Thalamus	tissue	22.7
Substantia nigra	tissue	22.7
Pons	tissue	22.6
Midbrain	tissue	22.2
Duodenum	tissue	22.2	low
Liver	tissue	21.6	medium
Corpus callosum	tissue	21.2
Cervix	tissue	20.1	not detected
Lymph node	tissue	20.1	medium
Ovary	tissue	20.1	low
Gallbladder	tissue	19.5	medium
Testis	tissue	19.3	high
Tongue	tissue	18.8
Hypothalamus	tissue	18.7
Urinary bladder	tissue	18.5	medium
Cerebral cortex	tissue	18.1	medium
Somatosensory cortex	tissue	18.1
Hippocampal formation	tissue	18.0
Skin 1	tissue	17.7	high
Motor cortex	tissue	17.4
Putamen	tissue	17.2
Periaqueductal gray	tissue	16.8
Prefrontal cortex	tissue	16.7
Ventral forebrain	tissue	16.6
Breast	tissue	16.5	high
Entorhinal cortex	tissue	16.3
Septum	tissue	16.3
Retrosplenial and cingulate cortex	tissue	16.1
Placenta	tissue	16.0	high
Retrosplenial cortex	tissue	16.0
Basal ganglia	tissue	15.9	medium
Kidney	tissue	15.9	high
Temporal cortex	tissue	15.8
Occipital cortex	tissue	15.8
Insular cortex	tissue	15.2

Brain sub-regions (HPA Brain Atlas): detected in 191; highest nTPM — Blood vessel (71.1), Arcuate nucleus (65.6), Nucleus ambiguus (59.9), Habenula (58.8), Lateral funiculus (white matter) (58.2).

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): KLF2

Functional genomics

gnomAD constraint: pLI 5.69e-33, LOEUF 1.71, missense Z -2.25 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD)

ENST00000371579 splits into 3 regions with different missense tolerance; 0 are missense-constrained. Missense variants in a constrained region (low observed/expected) are more likely to be pathogenic. gnomAD

Region (GRCh38)	Missense obs / exp	o/e	Constrained
9:137,110,651–137,114,006	624 / 531.2	1.17	no
9:137,114,007–137,114,296	15 / 37.0	0.41	no
9:137,114,297–137,114,713	168 / 124.1	1.35	no

Literature-anchored findings (GeneRIF, showing 5)

• catalytic properties and inhibition of this proline-specific enzyme (PMID:12529175)
• DPP II plays a minor role in the progression of malignant melanocytic lesions (PMID:18823758)
• DPP2 is essential for maintaining lymphocytes and fibroblasts in G(0), and its inhibition results in apoptosis mediated by induction of c-Myc and p53. (PMID:19556882)
• The constitutive expression of dipeptidyl peptidase II mRNA in chronic lymphocytic leukemia was demonstrated. (PMID:20534982)
• human DPP7 structures reveal the molecular basis of specific inhibition and the architectural diversity of proline-specific peptidases (PMID:22952628)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	dpp7	ENSDARG00000027750
mus_musculus	Dpp7	ENSMUSG00000026958
rattus_norvegicus	Dpp7	ENSRNOG00000012640
drosophila_melanogaster	CG3734	FBGN0038700
drosophila_melanogaster	CG18493	FBGN0038701
drosophila_melanogaster	CG3739	FBGN0038702
drosophila_melanogaster	CG11626	FBGN0038705
caenorhabditis_elegans		WBGENE00019682

Paralogs (2): PRSS16 (ENSG00000112812), PRCP (ENSG00000137509)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:1933213) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 11 distinct phenotype terms.

Mouse phenotype (MP)	Records
abnormal eating behavior	1
hyperglycemia	1
increased circulating insulin level	1
hepatic steatosis	1
increased liver weight	1
impaired glucose tolerance	1
insulin resistance	1
increased percent body fat/body weight	1
increased circulating glucose level	1
increased abdominal fat pad weight	1
increased epididymal fat pad weight	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Pongo abelii	Q5RBU7	99.2%	Diamond
Bos taurus	Q2TA14	78.3%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
MIR3621	ncRNA	100500811
TMEM210	protein-coding	100505993
GRIN1	protein-coding	2902
LRRC26	protein-coding	389816
MAN1B1-DT	ncRNA	100289341
UAP1L1	protein-coding	91373
MAN1B1	protein-coding	11253

Protein

Protein identifiers

Dipeptidyl peptidase 2 — Q9UHL4 (reviewed: Q9UHL4)

Alternative names: Dipeptidyl aminopeptidase II, Dipeptidyl peptidase 7, Dipeptidyl peptidase II, Quiescent cell proline dipeptidase

All UniProt accessions (8): A0A9L9PXE7, A0A9L9PXM1, A0A9L9PY12, A0ABB0MVF0, A0ABB0MVF1, Q9UHL4, R4GMV4, R4GN05

UniProt curated annotations — full annotation on UniProt →

Function. Plays an important role in the degradation of some oligopeptides.

Subunit / interactions. Homodimer.

Subcellular location. Lysosome. Cytoplasmic vesicle. Secreted.

Tissue specificity. Detected in seminal plasma (at protein level).

Post-translational modifications. N-glycosylated.

Similarity. Belongs to the peptidase S28 family.

RefSeq proteins (4): NP_001425037, NP_001425038, NP_001425039, NP_037511* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008758	Peptidase_S28	Family
IPR029058	AB_hydrolase_fold	Homologous_superfamily
IPR042269	Ser_carbopepase_S28_SKS	Homologous_superfamily

Pfam: PF05577

Enzyme classification (BRENDA)

• EC 3.4.14.2 — dipeptidyl-peptidase II (BRENDA: 10 organisms, 103 substrates, 205 inhibitors, 54 Km, 32 kcat entries)

Substrate kinetics (BRENDA)

37 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
GLY-PRO-4-NITROANILIDE	0.018–0.59	5
LYS-ALA-2-NAPHTHYLAMIDE	0.087–0.555	4
ALA-PRO-P-NITROANILIDE	0.009–0.041	3
GLY-PRO-P-NITROANILIDE	0.07–0.227	3
ALA-ALA-4-NITROANILIDE	0.487–1.22	2
ARG-PRO-4-NITROANILIDE	0.068–0.086	2
GLY-L-PRO-4-NITROANILIDE	0.36–1.1	2
L-LYS-L-ALA-7-AMIDO-4-METHYLCOUMARIN	0.36–0.93	2
LYS-ALA-P-NITROANILIDE	0.04–0.57	2
LYS-PRO-P-NITROANILIDE	0.019	2
ALA-ALA-ALA	1.67	1
ALA-PRO-4-NITROANILIDE	0.0457	1
ALA-PRO-AMINO-4-TRIFLUOROMETHYLCOUMARIN	0.032	1
ARG-PRO-2-NAPHTHYLAMIDE	0.0086	1
ARG-PRO-P-NITROANILIDE	0.04	1

UniProt features (50 total): helix 19, strand 13, glycosylation site 6, turn 4, active site 3, signal peptide 1, propeptide 1, sequence variant 1, sequence conflict 1, chain 1

Structure

Experimental structures (PDB)

3 structures by resolution:

PDB	Title	Method	Resolution (Å)
4EBB	Structure of DPP2	X-RAY DIFFRACTION	2
3JYH	Human dipeptidyl peptidase DPP7	X-RAY DIFFRACTION	2.19
3N0T	Human dipeptidil peptidase DPP7 complexed with inhibitor GSK237826A	X-RAY DIFFRACTION	2.45

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UHL4-F1	94.44	0.92

Human Protein Atlas

Protein class: Enzymes, ENZYME proteins, Hydrolases, Peptidases, Serine-type peptidases, Predicted secreted proteins, Plasma proteins

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): vesicles; golgi apparatus

Antibody reliability (HPA): IH enhanced · IF supported

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3)

Position	Role
162	charge relay system
418	charge relay system
443	charge relay system

Glycosylation sites (6)

Type	Positions
N-linked (glcnac…) asparagine	363, 428, 50, 86, 315, 356

Function

Pathways and Gene Ontology

Reactome pathways

1 curated (TAS) of 3; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

3 pathways:

ID	Pathway	Evidence
R-HSA-6798695	Neutrophil degranulation	curated
R-HSA-168256	Immune System	—
R-HSA-168249	Innate Immune System	—

MSigDB gene sets: 145 (showing top): REACTOME_INNATE_IMMUNE_SYSTEM, GOCC_SECRETORY_GRANULE, MODULE_151, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM1, GROSS_HYPOXIA_VIA_ELK3_UP, BYSTRYKH_HEMATOPOIESIS_STEM_CELL_AND_BRAIN_QTL_CIS, KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN, GOBP_PROTEIN_CATABOLIC_PROCESS, BURTON_ADIPOGENESIS_9, MODULE_114, GOCC_SECRETORY_VESICLE, GOCC_VESICLE_LUMEN

GO Biological Process (2): proteolysis (GO:0006508), protein catabolic process (GO:0030163)

GO Molecular Function (6): aminopeptidase activity (GO:0004177), serine-type peptidase activity (GO:0008236), dipeptidyl-peptidase activity (GO:0008239), serine-type exopeptidase activity (GO:0070008), peptidase activity (GO:0008233), hydrolase activity (GO:0016787)

GO Cellular Component (6): extracellular region (GO:0005576), vesicle (GO:0031982), azurophil granule lumen (GO:0035578), extracellular exosome (GO:0070062), lysosome (GO:0005764), cytoplasmic vesicle (GO:0031410)

Reactome top-level categories

2 top-level categories:

Category	Pathways
Innate Immune System	1
Immune System	1

GO top-level categories

18 GO namespaces:

Category	Terms
exopeptidase activity	3
protein metabolic process	2
macromolecule catabolic process	1
peptidase activity	1
serine hydrolase activity	1
serine-type peptidase activity	1
hydrolase activity	1
catalytic activity, acting on a protein	1
catalytic activity	1
cellular anatomical structure	1
membrane-bounded organelle	1
vacuolar lumen	1
secretory granule lumen	1
azurophil granule	1
extracellular vesicle	1
lytic vacuole	1
cytoplasm	1
intracellular vesicle	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 2 of 14 annotations. The rest are phylogenetic / computational / electronic (IEA).

2 experimentally-supported GO terms:

GO term	NS	Evidence
extracellular exosome	CC	high-throughput assay
vesicle	CC	direct assay

Protein interactions and networks

STRING

showing 15 of 900 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DPP7	DPP4	P27487	866
DPP7	TIMM8B	Q9Y5J9	843
DPP7	DPP8	Q6V1X1	808
DPP7	DPP9	Q86TI2	790
DPP7	TIMM8A	O60220	755
DPP7	DPP3	Q9NY33	677
DPP7	SDHD	O14521	663
DPP7	SDHC	Q99643	660
DPP7	PREP	P48147	655
DPP7	CTSC	P53634	624
DPP7	FAP	Q12884	610
DPP7	SDHB	P21912	609
DPP7	PEPD	P12955	593
DPP7	GOLGA3	Q08378	569
DPP7	DPP10	Q8N608	554

IntAct

Human interaction partners of DPP7 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

4 partners by confidence:

Partner	Interaction type	MIscore	Records
CFTR	physical association	0.370	1
TFAP2A	physical association	0.370	1
TFAP2C	physical association	0.370	1
XRN1	physical association	0.000	1

BioGRID (41 interactions; top human partners by supporting records): ABI1 (Affinity Capture-MS), AIMP1 (Co-fractionation), CEP78 (Affinity Capture-MS), CFTR (PCA), CSK (Affinity Capture-MS), CSTB (Co-fractionation), DOK2 (Affinity Capture-MS), FBXO6 (Affinity Capture-MS), HCK (Affinity Capture-MS), KIAA1429 (Affinity Capture-MS), MAP2K1 (Affinity Capture-MS), MYCBP (Co-fractionation), MYL12B (Affinity Capture-MS), NUDT21 (Affinity Capture-RNA), OBSL1 (Affinity Capture-MS)

Disease & clinical

Genetic variants

Variant evidence for DPP7: 176 ClinVar records (0 pathogenic / likely pathogenic); 1 GWAS association.

ClinVar

176 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	137
Likely benign	8
Benign	0

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 22 predictions of 977):

Position(s)	Effect	Δscore	Sites
9:137110870	donor_gain	1.0000
9:137110878–137110879	donor_loss	1.0000	4
9:137110959	acceptor_gain	1.0000
9:137111921	donor_gain	1.0000
9:137112951–137112952	donor_loss	1.0000	5
9:137113120–137113121	acceptor_loss	1.0000	3
9:137113124	acceptor_gain	1.0000
9:137113208	donor_gain	1.0000
9:137113498	acceptor_loss	1.0000	2
9:137113863–137113864	donor_loss	1.0000	3

AlphaMissense

1,208 missense substitutions predicted likely pathogenic (of 3,187 scored), across 293 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
D418	8	0.990	0.993
D137	8	0.977	0.987
H443	8	0.976	0.996
D446	8	0.968	0.978
H107	8	0.966	0.989
D334	8	0.964	0.982
F368	8	0.963	0.997
D366	8	0.961	0.987
D454	8	0.961	0.983
S162	8	0.960	0.991
D348	8	0.953	0.987
H444	8	0.947	0.981
D41	8	0.941	0.969
S186	8	0.933	0.993
F104	8	0.924	0.987
F412	8	0.907	0.977
F43	8	0.891	0.974
F84	8	0.890	0.977
H42	8	0.874	0.956
F266	8	0.866	0.964

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

4 prognostic cancer types:

Cancer	Prognostic	p-value
Kidney Renal Clear Cell Carcinoma (TCGA)	favorable	0.000116
Colon Adenocarcinoma (TCGA)	unfavorable	0.000188
Colon Adenocarcinoma (validation)	unfavorable	0.000506
Pancreatic Adenocarcinoma (TCGA)	favorable	0.000778

Disease associations

OMIM: gene MIM:610537 | disease phenotypes:

GWAS associations

1 associations:

Study	Trait	p-value
GCST005024_111	Pursuit maintenance gain	2e-6

EFO canonical traits (from GWAS)

1 canonical traits:

EFO ID	Trait name
EFO:0008433	pursuit maintenance gain measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL2111469 (SELECTIVITY GROUP), CHEMBL3976 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

Phase ≥1, by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 38,302 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

3 molecules by phase:

Molecule	Name	Phase	Patents
CHEMBL515387	GOSOGLIPTIN	4	823
CHEMBL1422	SITAGLIPTIN	4	26,952
CHEMBL67279	TALABOSTAT	3	10,527

PharmGKB: 1 entry (CPIC guideline: no)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — S28: Lysosomal Pro-Xaa carboxypeptidase

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
UAMC00039	Inhibition	10.1	pKi

Binding affinities (BindingDB)

1097 measured of 1692 human assays (1707 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
[(2R)-1-[(2S)-2-aminopropanethioyl]pyrrolidin-2-yl]boronic acid	IC50	0.2 nM	US-11559537: Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists
Boronic acid derivative	IC50	0.2 nM	US-11559537: Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists
N4-(4-chlorobenzyl)-2,4-diaminobutanoylpiperidine	IC50	0.22 nM
(S)-2-Amino-4-[(4-chloro-benzyl)-methyl-amino]-1-piperidin-1-yl-butan-1-one	IC50	0.22 nM
2-(S)-Amino-4-(2-chloro-benzylamino)-1-piperidin-1-yl-butan-1-one	IC50	0.23 nM
2-(S)-Amino-4-(2-benzyloxy-benzylamino)-1-piperidin-1-yl-butan-1-one	IC50	0.39 nM
(S)-2-Amino-4-(4-chloro-benzylamino)-1-(4-fluoro-piperidin-1-yl)-butan-1-one	IC50	0.39 nM
2-(S)-Amino-4-(4-benzyloxy-benzylamino)-1-piperidin-1-yl-butan-1-one	IC50	0.41 nM
(S)-2,4-Diamino-N-((R)-1-boron-dihydroxide-pentyl)-butyramide	IC50	0.48 nM
(R)-1-((S)-2,4-diaminobutanamido)pentylboronic acid	IC50	0.48 nM
(S)-2-Amino-4-(4-chloro-benzylamino)-1-(4-methyl-piperidin-1-yl)-butan-1-one	IC50	0.55 nM
(S)-2-Amino-4-dibenzylamino-1-piperidin-1-yl-butan-1-one	IC50	0.6 nM
(S)-2-Amino-4-(4-chloro-benzylamino)-1-(3-fluoro-piperidin-1-yl)-butan-1-one	IC50	0.62 nM
(2S,4S)-4-(4-chlorobenzylamino)-2-amino-1-(piperidin-1-yl)pentan-1-one	IC50	0.62 nM
2-(S)-Amino-4-(4-methoxy-benzylamino)-1-piperidin-1-yl-butan-1-one	IC50	0.66 nM
(S)-2,4-Diamino-1-(2-boron-dihydroxide-pyrrolidin-1-yl)-butan-1-one	IC50	0.72 nM
2-(S)-Amino-1-piperidin-1-yl-4-[(pyridin-4-ylmethyl)-amino]-butan-1-one	IC50	0.75 nM
Boronic acid derivative	IC50	0.8 nM	US-11559537: Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists
2-(S)-Amino-1-piperidin-1-yl-4-[(thiophen-2-ylmethyl)-amino]-butan-1-one	IC50	0.8 nM
(S)-2,4-diamino-1-((3aR,6aR)-hexahydrocyclopenta[b]pyrrol-1(2H)-yl)butan-1-one	IC50	0.88 nM
2-(S)-Amino-4-phenethylamino-1-piperidin-1-yl-butan-1-one	IC50	0.9 nM
(R)-1-((S)-2-aminopropanoyl)pyrrolidin-2-ylboronic acid	IC50	1 nM	US-11559537: Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists
Boronic acid derivative	IC50	1 nM	US-11559537: Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists
N-alkyl Gly-boro-Pro derivative	IC50	1 nM
2-(S)-Amino-4-(cyclohexylmethyl-amino)-1-piperidin-1-yl-butan-1-one	IC50	1.1 nM
(S)-2-Amino-4-(4-chloro-benzylamino)-1-(3,6-dihydro-2H-pyridin-1-yl)-butan-1-one	IC50	1.1 nM
2-(S)-Amino-4-[(naphthalen-2-ylmethyl)-amino]-1-piperidin-1-yl-butan-1-one	IC50	1.1 nM
(S)-2-Amino-4-(4-chloro-benzylamino)-1-(3-methyl-piperidin-1-yl)-butan-1-one	IC50	1.13 nM
2-(S)-Amino-4-[(naphthalen-1-ylmethyl)-amino]-1-piperidin-1-yl-butan-1-one	IC50	1.31 nM
2-(S)-Amino-4-(3-chloro-benzylamino)-1-piperidin-1-yl-butan-1-one	IC50	1.34 nM
(S)-2-Amino-4-phenylamino-1-piperidin-1-yl-butan-1-one	IC50	1.5 nM
N-((S)-3-Amino-4-oxo-4-piperidin-1-yl-butyl)-acetamide	IC50	1.5 nM
2-(S)-Amino-4-(3-methoxy-benzylamino)-1-piperidin-1-yl-butan-1-one	IC50	1.77 nM
N-((S)-3-Amino-4-oxo-4-piperidin-1-yl-butyl)-guanidine	IC50	1.8 nM
N-alkyl Gly-boro-Pro derivative	IC50	1.8 nM
2-(S)-Amino-4-(3-phenyl-propylamino)-1-piperidin-1-yl-butan-1-one	IC50	1.91 nM
(S)-2-(S)-Amino-1-(2-boron-dihydroxide-pyrrolidin-1-yl)-hexan-1-one	IC50	2 nM
2-(S)-Amino-4-benzylamino-1-piperidin-1-yl-butan-1-one	IC50	2.03 nM
[(2R)-1-[(2S)-2-amino-2-cyclohexylacetyl]pyrrolidin-2-yl]boronic acid	IC50	2.1 nM	US-11559537: Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists
2-Cyclodecylamino-1-pyrrolidin-1-yl–2-borandihydroxy-ethanone	IC50	2.2 nM
(S)-2-Amino-4-(4-chloro-benzylamino)-1-(2-methyl-piperidin-1-yl)-butan-1-one	IC50	2.3 nM
3-[((S)-3-Amino-4-oxo-4-piperidin-1-yl-butylamino)-methyl]-benzonitrile	IC50	2.7 nM
2-(S)-Amino-4-(2,4-dimethoxy-benzylamino)-1-piperidin-1-yl-butan-1-one	IC50	2.7 nM
(2S,3S)-2-amino-3-(4’-fluorobiphenyl-4-yl)-1-((S)-3-fluoropyrrolidin-1-yl)butan-1-one	IC50	2.7 nM
Boronic acid derivative	IC50	2.9 nM	US-11559537: Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists
(2S,4S)-4-(4-chlorobenzylamino)-2-amino-1-(piperidin-1-yl)hexan-1-one	IC50	3.4 nM
2,6-Diamino-hexanoic acid ((R)-1-boron-dihydroxide-pentyl)-amide	IC50	3.7 nM
(2S,4S)-4-(4-chlorobenzylamino)-2-amino-5-phenyl-1-(piperidin-1-yl)pentan-1-one	IC50	3.8 nM
1-((S)-2-Amino-4-benzylamino-butyryl)-piperidine-2-carbonitrile	IC50	4 nM
2-Cyclooctonylamino-1-pyrrolidin-1-yl–2-borandihydroxy-ethanone	IC50	4 nM

ChEMBL bioactivities

647 potent at pChembl≥5 of 1214 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.09	Ki	0.082	nM	CHEMBL98869
10.09	Ki	0.082	nM	CHEMBL5723377
9.85	IC50	0.14	nM	CHEMBL5723377
9.68	IC50	0.21	nM	CHEMBL5723377
9.66	IC50	0.22	nM	CHEMBL98869
9.66	IC50	0.22	nM	CHEMBL98801
9.64	IC50	0.23	nM	CHEMBL98762
9.41	IC50	0.39	nM	CHEMBL99506
9.41	IC50	0.39	nM	CHEMBL418979
9.39	IC50	0.41	nM	CHEMBL99247
9.32	IC50	0.48	nM	CHEMBL194354
9.32	IC50	0.48	nM	CHEMBL398076
9.32	IC50	0.48	nM	CHEMBL5723377
9.32	IC50	0.48	nM	CHEMBL98869
9.26	IC50	0.55	nM	CHEMBL98148
9.22	IC50	0.6	nM	CHEMBL97970
9.21	IC50	0.62	nM	CHEMBL215299
9.21	IC50	0.62	nM	CHEMBL98060
9.18	IC50	0.66	nM	CHEMBL99047
9.14	IC50	0.72	nM	CHEMBL194428
9.12	IC50	0.75	nM	CHEMBL99111
9.10	IC50	0.8	nM	CHEMBL98423
9.06	IC50	0.88	nM	CHEMBL397057
9.05	IC50	0.9	nM	CHEMBL317312
9.00	IC50	1	nM	CHEMBL372180
8.96	IC50	1.1	nM	CHEMBL98860
8.96	IC50	1.1	nM	CHEMBL100370
8.96	IC50	1.1	nM	CHEMBL97977
8.95	IC50	1.13	nM	CHEMBL317950
8.88	IC50	1.31	nM	CHEMBL97884
8.87	IC50	1.34	nM	CHEMBL317949
8.82	IC50	1.5	nM	CHEMBL98415
8.82	IC50	1.5	nM	CHEMBL440325
8.75	IC50	1.77	nM	CHEMBL327499
8.74	IC50	1.8	nM	CHEMBL196933
8.74	IC50	1.8	nM	CHEMBL101401
8.72	IC50	1.91	nM	CHEMBL430661
8.70	IC50	2	nM	CHEMBL194852
8.69	IC50	2.03	nM	CHEMBL99263
8.66	IC50	2.2	nM	CHEMBL196267
8.64	IC50	2.3	nM	CHEMBL319520
8.57	IC50	2.7	nM	CHEMBL237336
8.57	IC50	2.7	nM	CHEMBL330600
8.57	IC50	2.7	nM	CHEMBL99260
8.47	IC50	3.4	nM	CHEMBL215244
8.43	IC50	3.7	nM	CHEMBL194517
8.42	IC50	3.8	nM	CHEMBL214630
8.40	IC50	4	nM	CHEMBL382974
8.40	IC50	4	nM	CHEMBL329314
8.39	IC50	4.1	nM	CHEMBL371130

PubChem BioAssay actives

728 with measured affinity, of 2395 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(2S)-2-amino-4-[(4-chlorophenyl)methylamino]-1-piperidin-1-ylbutan-1-one	343975: Inhibition of DPP2	ki	0.0001	uM
(2S)-2-amino-4-[(4-chlorophenyl)methyl-methylamino]-1-piperidin-1-ylbutan-1-one	56221: Inhibition of human Dipeptidylpeptidase II (DPP II)	ic50	0.0002	uM
(2S)-2-amino-4-[(2-chlorophenyl)methylamino]-1-piperidin-1-ylbutan-1-one	56221: Inhibition of human Dipeptidylpeptidase II (DPP II)	ic50	0.0002	uM
(2S)-2-amino-4-[(4-phenylmethoxyphenyl)methylamino]-1-piperidin-1-ylbutan-1-one	56221: Inhibition of human Dipeptidylpeptidase II (DPP II)	ic50	0.0004	uM
(2S)-2-amino-4-[(2-phenylmethoxyphenyl)methylamino]-1-piperidin-1-ylbutan-1-one	56221: Inhibition of human Dipeptidylpeptidase II (DPP II)	ic50	0.0004	uM
(2S)-2-amino-4-[(4-chlorophenyl)methylamino]-1-(4-fluoropiperidin-1-yl)butan-1-one	56221: Inhibition of human Dipeptidylpeptidase II (DPP II)	ic50	0.0004	uM
[(1R)-1-[[(2S)-2,4-diaminobutanoyl]amino]pentyl]boronic acid	305098: Inhibition of human DPP2	ic50	0.0005	uM
[(1S)-1-[[(2S)-2,4-diaminobutanoyl]amino]pentyl]boronic acid	254911: Inhibitory concentration against human dipeptidylpeptidase 7	ic50	0.0005	uM
(2S)-2-amino-4-[(4-chlorophenyl)methylamino]-1-(4-methylpiperidin-1-yl)butan-1-one	56221: Inhibition of human Dipeptidylpeptidase II (DPP II)	ic50	0.0006	uM
(2S)-2-amino-4-[(4-chlorophenyl)methylamino]-1-(3-fluoropiperidin-1-yl)butan-1-one	56221: Inhibition of human Dipeptidylpeptidase II (DPP II)	ic50	0.0006	uM
(2S)-2-amino-4-(dibenzylamino)-1-piperidin-1-ylbutan-1-one	56221: Inhibition of human Dipeptidylpeptidase II (DPP II)	ic50	0.0006	uM
(2S,4S)-2-amino-4-[(4-chlorophenyl)methylamino]-1-piperidin-1-ylpentan-1-one	270815: Inhibition of DPP2	ic50	0.0006	uM
(2S)-2-amino-4-[(4-methoxyphenyl)methylamino]-1-piperidin-1-ylbutan-1-one	56221: Inhibition of human Dipeptidylpeptidase II (DPP II)	ic50	0.0007	uM
[(2S)-1-[(2S)-2,4-diaminobutanoyl]pyrrolidin-2-yl]boronic acid	254911: Inhibitory concentration against human dipeptidylpeptidase 7	ic50	0.0007	uM
(2S)-2-amino-1-piperidin-1-yl-4-(thiophen-2-ylmethylamino)butan-1-one	56221: Inhibition of human Dipeptidylpeptidase II (DPP II)	ic50	0.0008	uM
(2S)-2-amino-1-piperidin-1-yl-4-(pyridin-4-ylmethylamino)butan-1-one	56221: Inhibition of human Dipeptidylpeptidase II (DPP II)	ic50	0.0008	uM
(2S)-2-amino-4-(2-phenylethylamino)-1-piperidin-1-ylbutan-1-one	56221: Inhibition of human Dipeptidylpeptidase II (DPP II)	ic50	0.0009	uM
(2S)-1-[(3aR,6aR)-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrol-1-yl]-2,4-diaminobutan-1-one	305098: Inhibition of human DPP2	ic50	0.0009	uM
[(2R)-1-[2-[(4-pentyl-1-bicyclo[2.2.2]octanyl)amino]acetyl]pyrrolidin-2-yl]boronic acid	255032: Inhibitory activity against human DPP7 using Ala-Pro-AMC in fluorometric assay	ic50	0.0010	uM
(2S)-2-amino-4-(naphthalen-2-ylmethylamino)-1-piperidin-1-ylbutan-1-one	56221: Inhibition of human Dipeptidylpeptidase II (DPP II)	ic50	0.0011	uM
(2S)-2-amino-4-(cyclohexylmethylamino)-1-piperidin-1-ylbutan-1-one	56221: Inhibition of human Dipeptidylpeptidase II (DPP II)	ic50	0.0011	uM
(2S)-2-amino-4-[(4-chlorophenyl)methylamino]-1-(3,6-dihydro-2H-pyridin-1-yl)butan-1-one	56221: Inhibition of human Dipeptidylpeptidase II (DPP II)	ic50	0.0011	uM
(2S)-2-amino-4-[(4-chlorophenyl)methylamino]-1-(3-methylpiperidin-1-yl)butan-1-one	56221: Inhibition of human Dipeptidylpeptidase II (DPP II)	ic50	0.0011	uM
(2S)-2-amino-4-(naphthalen-1-ylmethylamino)-1-piperidin-1-ylbutan-1-one	56221: Inhibition of human Dipeptidylpeptidase II (DPP II)	ic50	0.0013	uM
(2S)-2-amino-4-[(3-chlorophenyl)methylamino]-1-piperidin-1-ylbutan-1-one	56221: Inhibition of human Dipeptidylpeptidase II (DPP II)	ic50	0.0013	uM
N-[(3S)-3-amino-4-oxo-4-piperidin-1-ylbutyl]acetamide	56221: Inhibition of human Dipeptidylpeptidase II (DPP II)	ic50	0.0015	uM
(2S)-2-amino-4-anilino-1-piperidin-1-ylbutan-1-one	56221: Inhibition of human Dipeptidylpeptidase II (DPP II)	ic50	0.0015	uM
2-[(3S)-3-amino-4-oxo-4-piperidin-1-ylbutyl]guanidine	56221: Inhibition of human Dipeptidylpeptidase II (DPP II)	ic50	0.0018	uM
(2S)-2-amino-4-[(3-methoxyphenyl)methylamino]-1-piperidin-1-ylbutan-1-one	56221: Inhibition of human Dipeptidylpeptidase II (DPP II)	ic50	0.0018	uM
[(2R)-1-[2-(cycloheptylamino)acetyl]pyrrolidin-2-yl]boronic acid	255032: Inhibitory activity against human DPP7 using Ala-Pro-AMC in fluorometric assay	ic50	0.0018	uM
(2S)-2-amino-4-(3-phenylpropylamino)-1-piperidin-1-ylbutan-1-one	56221: Inhibition of human Dipeptidylpeptidase II (DPP II)	ic50	0.0019	uM
[(2S)-1-[(2S)-2-aminohexanoyl]pyrrolidin-2-yl]boronic acid	254911: Inhibitory concentration against human dipeptidylpeptidase 7	ic50	0.0020	uM
(2S)-2-amino-4-(benzylamino)-1-piperidin-1-ylbutan-1-one	56221: Inhibition of human Dipeptidylpeptidase II (DPP II)	ic50	0.0020	uM
[(2R)-1-[2-(cyclodecylamino)acetyl]pyrrolidin-2-yl]boronic acid	255032: Inhibitory activity against human DPP7 using Ala-Pro-AMC in fluorometric assay	ic50	0.0022	uM
(2S)-2-amino-4-[(4-chlorophenyl)methylamino]-1-(2-methylpiperidin-1-yl)butan-1-one	56221: Inhibition of human Dipeptidylpeptidase II (DPP II)	ic50	0.0023	uM
3-[[[(3S)-3-amino-4-oxo-4-piperidin-1-ylbutyl]amino]methyl]benzonitrile	56221: Inhibition of human Dipeptidylpeptidase II (DPP II)	ic50	0.0027	uM
(2S)-2-amino-4-[(2,4-dimethoxyphenyl)methylamino]-1-piperidin-1-ylbutan-1-one	56221: Inhibition of human Dipeptidylpeptidase II (DPP II)	ic50	0.0027	uM
(2S,3S)-2-amino-3-[4-(4-fluorophenyl)phenyl]-1-[(3S)-3-fluoropyrrolidin-1-yl]butan-1-one	393710: Inhibition of QPP	ic50	0.0027	uM
(2S,4S)-2-amino-4-[(4-chlorophenyl)methylamino]-1-piperidin-1-ylhexan-1-one	270815: Inhibition of DPP2	ic50	0.0034	uM
[(1S)-1-[[(2S)-2,6-diaminohexanoyl]amino]pentyl]boronic acid	254911: Inhibitory concentration against human dipeptidylpeptidase 7	ic50	0.0037	uM
(2S,4S)-2-amino-4-[(4-chlorophenyl)methylamino]-5-phenyl-1-piperidin-1-ylpentan-1-one	270815: Inhibition of DPP2	ic50	0.0038	uM
1-[(2S)-2-amino-4-(benzylamino)butanoyl]piperidine-2-carbonitrile	56221: Inhibition of human Dipeptidylpeptidase II (DPP II)	ic50	0.0040	uM
[(2R)-1-[2-(cyclooctylamino)acetyl]pyrrolidin-2-yl]boronic acid	255032: Inhibitory activity against human DPP7 using Ala-Pro-AMC in fluorometric assay	ic50	0.0040	uM
[(2R)-1-[2-(cyclohexylamino)acetyl]pyrrolidin-2-yl]boronic acid	255032: Inhibitory activity against human DPP7 using Ala-Pro-AMC in fluorometric assay	ic50	0.0041	uM
(2S)-2-amino-4-[bis[(4-chlorophenyl)methyl]amino]-1-piperidin-1-ylbutan-1-one	56221: Inhibition of human Dipeptidylpeptidase II (DPP II)	ic50	0.0042	uM
6-[[(3S)-3-amino-4-oxo-4-piperidin-1-ylbutyl]amino]pyridine-3-carbonitrile	56221: Inhibition of human Dipeptidylpeptidase II (DPP II)	ic50	0.0046	uM
[(1S)-1-[[(2S)-2,5-diaminopentanoyl]amino]pentyl]boronic acid	254911: Inhibitory concentration against human dipeptidylpeptidase 7	ic50	0.0047	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148261: Binding affinity to human DPP7 incubated for 45 mins by Kinobead based pull down assay	kd	0.0053	uM
[(2R)-1-[(2R)-2-aminopropanoyl]pyrrolidin-2-yl]boronic acid	255032: Inhibitory activity against human DPP7 using Ala-Pro-AMC in fluorometric assay	ic50	0.0063	uM
1-[(2S)-2-amino-4-[(4-chlorophenyl)methylamino]butanoyl]piperidine-2-carbonitrile	56221: Inhibition of human Dipeptidylpeptidase II (DPP II)	ic50	0.0065	uM

CTD chemical–gene interactions

40 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases expression	2
UAMC00039	decreases reaction, increases cleavage, increases abundance, decreases activity	2
Valproic Acid	decreases expression, increases methylation	2
bisphenol F	increases expression	1
methylmercuric chloride	decreases expression	1
sodium arsenate	increases abundance, increases expression	1
4-nitroaniline	increases abundance, increases cleavage, increases reaction, decreases reaction	1
ferrous chloride	decreases expression	1
nickel sulfate	decreases expression	1
benzyloxycarbonylleucyl-leucyl-leucine aldehyde	increases abundance, increases cleavage, increases reaction	1
alanylproline-4-nitroanilide	increases cleavage, decreases reaction	1
ICG 001	increases expression	1
bisphenol B	increases expression	1
bisphenol S	increases expression	1
jinfukang	affects cotreatment, increases expression	1
(+)-JQ1 compound	decreases expression	1
bisphenol AF	increases expression	1
Temozolomide	decreases expression	1
Sunitinib	increases expression	1
Air Pollutants	affects expression, increases abundance	1
Arbutin	decreases expression	1
Arsenic	increases abundance, increases expression	1
Benzo(a)pyrene	increases expression	1
Cisplatin	affects cotreatment, increases expression	1
Diazinon	increases methylation	1
Dipeptides	increases abundance, increases cleavage, increases reaction, decreases reaction	1
Estradiol	increases expression	1
Ethyl Methanesulfonate	decreases expression	1
Etoposide	increases abundance, increases cleavage, increases reaction	1
Formaldehyde	decreases expression	1

ChEMBL screening assays

147 unique, capped per target: 142 binding, 4 functional, 1 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL665781	Binding	Selectivity index of compound was determined for human Dipeptidylpeptidase IV to that of Dipeptidyl-peptidase II	Design, synthesis, and SAR of potent and selective dipeptide-derived inhibitors for dipeptidyl peptidases. — *J Med Chem*
CHEMBL4617710	ADMET	Inhibition of mammalian DPP7 (unknown origin) using H-Lys-Pro-AMC as substrate preincubated for 10 mins followed by substrate addition measured after 30 mins	Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases. — *J Med Chem*
CHEMBL5723296	Functional	Affinity Biochemical interaction: (enzymatic assay (fluorogenic substrate cleavage)) EUB0002750aCl DPP7	Affinity Biochemical Literature for EUbOPEN Chemogenomic Library

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for DPP7 across ~30M SureChEMBL compounds — explore on Sugi Predict.